ENDRA Life Sciences Reports Q2 EPS ($1.71) vs. (8c) Last Year, Redesigns TAEUS Probe for Liver Health Assessment

Endra Life Sciences reported Q2 EPS of $1.71, compared to a loss of 8 cents last year. The company has $1.8 million in cash and cash equivalents, which it will use to execute its near-term operational and regulatory milestones. Endra's redesigned TAEUS probe is a major advancement in non-invasive liver health assessment, with early data showing promising results. The company aims to bring liver diagnostics into everyday care and enable earlier detection and better treatment decisions for metabolic diseases.

Endra Life Sciences (NASDAQ:NDRA) has reported its second-quarter (Q2) earnings per share (EPS) of $1.71, which compares favorably to the loss of $0.08 in the same period last year. The company's Q2 operating expenses decreased by 42% year-over-year to $1.3 million, driven by cost-optimization measures such as streamlined staffing and reduced overhead [1].

Endra's net loss narrowed to $1.2 million from $2.2 million in the year-ago period, reflecting improved operational efficiency. The company reported $1.8 million in cash and cash equivalents as of June 30, 2025, providing resources to execute its near-term operational and regulatory milestones [1].

The company's redesigned TAEUS probe represents a significant advancement in non-invasive liver health assessment. Early data has shown promising results, aligning with Endra's goal of bringing liver diagnostics into everyday care. This technology aims to enable earlier detection and better treatment decisions for metabolic diseases [2].

Endra's strategic focus on liver diagnostics is timely, given the growing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), which are often underdiagnosed. The company's innovative solutions are designed to address the limitations of existing non-invasive methods and support the growing demand for accessible, non-invasive liver diagnostics and treatment [2].

References:
[1] https://seekingalpha.com/news/4485759-endra-life-sciences-gaap-eps-of-1_71-beats-by-0_56
[2] https://www.morningstar.com/news/business-wire/20250812484826/fda-grants-510k-clearance-for-sonic-incytes-velacur-one-ai-guided-point-of-care-ultrasound-for-the-management-of-chronic-liver-diseases